Clinical study to assess the efficacy and safety of increased dose of TA-650 (infliximab) in patients with Crohn's disease (CD).
Phase of Trial: Phase III
Latest Information Update: 11 Feb 2018
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 15 Dec 2011 Actual patient number is 39 according to ClinicalTrials.gov.
- 21 Sep 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 21 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.